ArticleAnnals of pediatric cardiology
Parvovirus B19-associated fulminant acute myocarditis in children during the fifth disease outbreak in 2024: What should we learn?
Article in Annals of pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocarditis is a significant cause of cardiac morbidity in children, with viral infections, including Parvovirus B19 (PVB19), among the most implicated agents. Recent epidemiological reports suggest a resurgence of PVB19 infections post-COVID-19, raising concerns about associated myocarditis. We aimed to retrospectively analyze clinical, laboratory, and imaging data of patients with PVB19-associated myocarditis in 2024. We included 5 pediatric patients admitted with acute myocarditis and positive blood PVB19-DNA. Median age was 6.4 years; 80% were male. Most patients presented with cardiogenic shock; two required extracorporeal membrane oxygenation. Echocardiography revealed severely reduced left ventricular ejection fraction (median 25%), atrial enlargement, and mitral insufficiency. No direct correlation was found between PVB19 DNA load and disease severity. Immunomodulatory therapy, including IVIG (intravenous immunoglobulin) and corticosteroids, was administered in most cases, with variable outcomes. Three patients had viral coinfections, raising concern for a potential link with worse outcomes. Following the SARS-CoV-2 pandemic, an apparent increase in pediatric myocarditis has been observed. The 2024 outbreak of PVB19 infections was associated with an unusual number of fulminant myocarditis cases, particularly in infants. However, our small sample precludes definitive conclusions. Larger multicenter studies are needed to clarify the role of PVB19 and coinfections in pediatric myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.